IL6 and rheumatoid arthritis: For instance, isorhamnetin demonstrated the ability to attenuate the expression levels of NF-κB and p38 mRNA, thereby inhibiting the release of TNF-α, IL-6, and IL-8 through the NF-κB and p38 MAPK signaling pathways, ultimately ameliorating clinical symptoms in RA mice [55].